Popular

Due to the high absorption rates in its flagship offerings, Plandaí Biotechnology Inc. (OTCQB – PLPL - $0.52 - Spec Buy) may soon enter the colon cancer fighting arena.

The medical marijuana industry received a major boost recently at the annual United States Conference of Mayors. A unanimous and bipartisan resolution urging the federal government to let states decide for themselves how to handle marijuana policy passed with no speakers rising in opposition.

Professional and amateur athletes alike are constantly seeking an advantage to fight muscle fatigue and improve physical performance.  There have been countless scandals in professional sports related to illegal or banned performance enhancing drugs.

Today we are releasing an update on PetroTech Oil & Gas Inc. (OTCPK – PTOG), our most recent initiation. Although the stock has gone down in concert with the market, management’s recent and pending progress are great signs for the near term and the lower price is a great entry point for investors.

The Company’s 2 clinical trials clearly illustrate the great potential efficacy in using encapsulated cells with a pro-drug as a targeting device for the treatment of solid pancreatic and mammary tumors, which will substantially raise Nuvilex’s profile and valuation.

Plandai’s Phytofare™ Catechin Complex is derived from Green Tea that could prove to be used to target the large anti-aging market. Catechins found in green tea, such as EGCG (Epigallocatechin Gallate), are powerful antioxidants that can support a healthier immune system and be used as a treatment for multitude of conditions, including sunburn, and even help rejuvenate skin cells.

Considering that Nuvilex likely has much greater experience in successfully conducting oncology clinical trials than any other player in the space, it is anecdotal evidence such as the San Francisco study that may serve to shorten Nuvilex’s own overall research and development times. Thus, Nuvilex’s combination CBD-based cancer studies with live-cell encapsulation-based therapies might result in bringing a highly effective product potentially worth billions to market in a shorter period of time than its competitors.

With substantial absorption advantages, the innovative delivery system under development and the potential adaptability of its core offerings for the prevention and treatment of a multitude of conditions, Plandaí is poised to serve as a supplier of the next generation of improved nutraceutical ingredients.